# Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

> **NCT01289457** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 282 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01289457
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-02
- **Primary completion:** 2017-06-28
- **Final completion:** 2017-06-28
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01289457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01289457, "Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01289457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*